NCT03676114

Brief Summary

Breast cancer patients often have perioperative emotional disorders such as anxiety and depression, which can lead to poor quality of recovery.This study aims to determine whether ketamine could improve the quality of recovery in breast cancer patients. Meanwhile, it will show if ketamine could improve anxiety, depression, postoperative pain and fatigue.This trial also will bring great concerns on patients' mental health perioperatively and explore the measures to improve their quality of life.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P25-P50 for phase_4 breast-cancer

Timeline
Completed

Started Sep 2018

Shorter than P25 for phase_4 breast-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 5, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 18, 2018

Completed
2 days until next milestone

Study Start

First participant enrolled

September 20, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

September 21, 2018

Status Verified

September 1, 2018

Enrollment Period

1 year

First QC Date

September 5, 2018

Last Update Submit

September 19, 2018

Conditions

Keywords

KetamineBreast Cancer SurgeryPostoperative Recovery

Outcome Measures

Primary Outcomes (1)

  • QoR40 score

    Quality of recovery will be evaluated by Quality of Recovery 40 (QoR40),which assesses five dimensions of recovery (physical comfort,emotional state, physical independence , physiological support and pain ). Each item is rated on a five-point Likert scale: none of the time, some of the time, usually, most of the time, and all the time. The total score on the QoR40 ranges from 40 (poorest quality of recovery) to 200 (best quality of recovery).

    the first day after surgery

Secondary Outcomes (5)

  • ICFS scores

    Postoperative 3 days, 7 days and 30 days

  • HADS scores

    Postoperative 2 days and 3months

  • Chronic Pain

    3 months after surgery

  • NRS pain scores

    at 4 hours, 24 hours, and 48 hours after surgery

  • Postoperative complications

    Postoperative 1 day, 2 days and 3 days

Study Arms (2)

ketamine group

EXPERIMENTAL
Drug: ketamine

normal saline group

PLACEBO COMPARATOR
Drug: Normal saline

Interventions

0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation

ketamine group

Same volume of normal saline will be administrated

normal saline group

Eligibility Criteria

Age20 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists Grade I-II
  • Patients undergoing elective breast cancer surgery under general anesthesia

You may not qualify if:

  • Unstable hypertension, history of heart disease
  • Hepatic or renal dysfunction
  • Patients undergoing chemotherapy before surgery
  • Have a history of chronic pain or chronic use of analgesic
  • Have mental illness or can't cooperate with investigators
  • Have a history of ketamine allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesia of the Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Interventions

KetamineSaline Solution

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Doctor-in-charge of Anesthetist

Study Record Dates

First Submitted

September 5, 2018

First Posted

September 18, 2018

Study Start

September 20, 2018

Primary Completion

October 1, 2019

Study Completion

February 1, 2020

Last Updated

September 21, 2018

Record last verified: 2018-09

Locations